Home > Journals > Giornale Italiano di Dermatologia e Venereologia > Past Issues > Giornale Italiano di Dermatologia e Venereologia 2018 June;153(3) > Giornale Italiano di Dermatologia e Venereologia 2018 June;153(3):305-15



To subscribe
Submit an article
Recommend to your librarian


Publication history
Cite this article as



Giornale Italiano di Dermatologia e Venereologia 2018 June;153(3):305-15

DOI: 10.23736/S0392-0488.18.06006-6


language: English

Bullous pemphigoid: Italian guidelines adapted from the EDF/EADV guidelines

Emanuele COZZANI 1, Angelo V. MARZANO 2, Marzia CAPRONI 3, Claudio FELICIANI 4 , Piergiacomo CALZAVARA-PINTON 5, on behalf of Cutaneous Immunology group of SIDeMaST 

1 Clinic of Dermatology, University of Genoa, Genoa, Italy; 2 Unit of Dermatology, Department of Pathophysiology, Surgery, and Transplantation, University of Milan, Ca’ Granda Foundation and Institute for Research and Care, Maggiore Polyclinic Hospital, Milan, Italy; 3 Division of Rare Skin Diseases, Unit of Dermatology I, Piero Palagi Hospital, Usl Toscana Centro, University of Florence, Florence, Italy; 4 Clinic of Dermatology, University of Parma, Parma, Italy; 5 Clinic of Dermatology, University of Brescia, Brescia, Italy


Bullous pemphigoid is the most common autoimmune subepidermal blistering disease of the skin and mucous membranes. This disease typically affects the elderly and presents with itch and localized or generalized bullous lesions. In up to 20% of affected patients blister may be completely absent, and only excoriations, prurigo-like lesions, eczematous lesions, urticated lesions, and/or infiltrated plaques are observed. The disease is significantly associated with neurological disorders. The morbidity of bullous pemphigoid and its impact on the quality of life are significant. So far, a limited number of national treatment guidelines have been proposed, but no common European consensus has emerged. This guideline for the treatment of bullous pemphigoid has been developed by an Italian group of experts taking in account the Italian legislation and local pharmacological governance. Guidelines are adapted from the original article under the guidance of the European Dermatology Forum (EDF) in collaboration with the European Academy of Dermatology and Venereology (EADV). It summarizes evidence-based and expert-based recommendations (S2 level).

KEY WORDS: Bullous pemphigoid - Guideline - Rare diseases - Quality of life

top of page